US 11,918,649 B2
PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds
Eric Poma, New York, NY (US); Hilario Ramos, Austin, TX (US); Erin Willert, Round Rock, TX (US); Richard Shimkets, Commerce, GA (US); Crystal Jackson, Jefferson, GA (US); and Thomas Vincent, Athens, GA (US)
Assigned to Molecular Templates, Inc., Austin, TX (US)
Filed by Molecular Templates, Inc., Austin, TX (US)
Filed on Sep. 18, 2020, as Appl. No. 17/025,729.
Claims priority of provisional application 63/041,288, filed on Jun. 19, 2020.
Claims priority of provisional application 62/970,610, filed on Feb. 5, 2020.
Claims priority of provisional application 62/933,197, filed on Nov. 8, 2019.
Claims priority of provisional application 62/902,243, filed on Sep. 18, 2019.
Prior Publication US 2021/0079097 A1, Mar. 18, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 14/25 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/39558 (2013.01) [A61P 35/00 (2018.01); C07K 14/25 (2013.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2319/55 (2013.01)] 43 Claims
 
1. A method of treating cancer in a human subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a PD-L1 binding molecule comprising a Shiga toxin effector polypeptide and a binding region capable of specifically binding an extracellular part of PD-L1;
wherein the binding region comprises:
(a) a heavy chain variable region (VH) comprising:
(i) a CDR1 comprising the amino acid sequence EYTMH (SEQ ID NO:27),
(ii) a CDR2 comprising the amino acid sequence GINPNNGGTWYNQKFKG (SEQ ID NO:29), and
(iii) a CDR3 comprising the amino acid sequence PYYYGSREDYFDY (SEQ ID NO:32); and
(b) a light chain variable region (VL) comprising:
(i) a CDR1 comprising the amino acid sequence SASSSVSYMY (SEQ ID NO:19),
(ii) a CDR2 comprising the amino acid sequence LTSNLAS (SEQ ID NO:20), and
(iii) a CDR3 comprising the amino acid sequence QQWSSNPPT (SEQ ID NO:26); and
wherein the subject has the cancer, and wherein the cancer comprises PD-L1 expressing tumor cells.